FDA Advisory Committee Supports Use of Tobramycin Inhalation Powder from Novartis for Patients with Cystic Fibrosis
The Anti-Infective Drugs Advisory Committee (AIDAC) to the FDA voted 13 to 1 that there was adequate evidence of efficacy and safety to support the use of tobramycin inhalation powder (TIP) for the management of cystic fibrosis (CF) patients whose lungs contain bacteria called Pseudomonas aeruginosa (Pa).
The Anti-Infective Drugs Advisory Committee (AIDAC) to the FDA voted 13 to 1 that there was adequate evidence of efficacy and safety to support the use of tobramycin inhalation powder (TIP) for the management of cystic fibrosis (CF) patients whose lungs contain bacteria called Pseudomonas aeruginosa (Pa). Pa is the leading cause of loss of lung function in people with CF. TIP is intended for use in CF patients aged six years and older whose lung function is within a certain range (ie, FEV1 between 25% and 80% predicted).
The AIDAC based its recommendation on three Phase III clinical studies involving more than 650 CF patients aged 6 years and older, of whom 425 patients received at least one dose of TIP. The studies found that treatment with TIP resulted in improved lung function.
"While advances in research and medical treatments have substantially enhanced and extended the lives of patients with CF, the treatment burden remains very high," said TIP clinical investigator Michael Konstan, MD, chairman of the Department of Pediatrics and Director of the Cystic Fibrosis Center at Rainbow Babies and Children's Hospital and Case Western Reserve University School of Medicine in Cleveland, Ohio. "Today's vote is exciting for the CF community as TIP could reduce this treatment burden because of its shorter administration time and greater portability compared to nebulized tobramycin."
Tobramycin is currently marketed in the United States by Novartis Pharmaceuticals Corporation as TOBI (tobramycin inhalation solution, USP), and is administered as a nebulized solution with an indication similar to that proposed for TIP. In contrast, investigational TIP is a new inhaled formulation of tobramycin consisting of dry powder in capsules delivered via a dry powder inhaler. The new formulation was developed using proprietary Novartis PulmoSphere technology. This enabled the creation of hollow porous particles of tobramycin that can be delivered as a dry powder rather than as a nebulized solution.
"Novartis is committed to addressing the needs of patients with CF, and we are very encouraged by the Advisory Committee's vote to support the use of TIP in the [United States]," said Tim Wright, global head of development, Novartis Pharma. "The company is dedicated to introducing innovative, safe and effective treatment options for patients and physicians, and we look forward to working closely with the FDA as it finalizes its review of TIP."
CF is a life-threatening genetic disease that affects about 30,000 children and adults in the United States. It primarily impacts the lungs and digestive system, making it hard to breathe and to digest food. The treatment burden for CF is extremely high, with as many as 20 medications having to be used every day with a combined average treatment time of 108 minutes. The overall time to administer all the necessary treatments and perform physiotherapy and exercise can be as much as 2 to 3 hours each day.
Pa is a leading cause of loss of lung function in people with CF. About 80% of people with CF between the ages of 25 and 34 have Pa in their lungs. Once a CF patient is infected with Pa in their lungs, it never completely goes away.
The Phase III clinical trial program consisted of 2 trials comparing TIP to placebo and one trial comparing TIP to TOBI, at the proposed TIP dosage of 112 mg twice-daily (inhaling the contents of 4 28 mg capsules per dose) in a cycle of 28 days on, 28 days off treatment. Compared to patients on placebo, patients treated with TIP showed improved lung function. TIP also demonstrated comparable efficacy to TOBI 300 mg administered via a nebulizer with a reduction in administration time of approximately 70%, saving about 13 hours per treatment cycle. This does not include the time saved on setting up and maintaining the nebulizer and compressor.
The safety profile of TIP is similar to the profile of TOBI, other than local effects due to powder inhalation. In the Phase III clinical trial program, the most commonly reported adverse events with TIP were cough, lung disorder (ie, CF/pulmonary exacerbations), increased sputum, dyspnea and pyrexia.
Tobramycin inhalation powder is approved in 38 countries, including the European Union, Canada, Switzerland and Australia. TIP is currently available in Canada and a number of countries in the European Union under the brand-name TOBI Podhaler. The proposed brand-name in the United States, pending FDA approval, would be TOBI Podhaler.
TOBI (tobramycin inhalation solution, USP) is a prescription inhaled medication for cystic fibrosis patients whose lungs contain bacteria called Pseudomonas aeruginosa. TOBI has not been studied in patients under 6 years of age, in those with a lung function outside of a certain range, or in those whose lungs contain bacteria called Burkholderia cepacia.
IMPORTANT SAFETY INFORMATION
If patients are allergic to antibiotics in the same family as TOBI (ie, aminoglycosides), they should not take TOBI. They should tell their doctor before starting treatment if they have any history of hearing, kidney, balance, or muscle problems.
Patients taking TOBI may have temporary side effects like coughing or difficulty breathing. Some people taking TOBI experienced ringing in the ears, hearing loss, or changes in voice (hoarseness). Ringing in the ears may be a warning sign for hearing loss. If patients have ringing in the ears, changes in hearing, or dizziness, they should tell their doctor.
In studies, kidney damage was not seen in patients taking TOBI. However, antibiotics in the same family as TOBI have been linked to kidney damage.
If patients are pregnant, plan to become pregnant, or if they are breast-feeding, they should talk with their doctor before taking TOBI.
Some drugs may interact with TOBI. Patients should discuss all medications they are taking with their doctor.
Patients with cystic fibrosis can have many symptoms. Some of these may be related to their medications. They should tell their doctor if they have new or worsening symptoms.
Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch , or call 1-800-FDA-1088.
Please visit www.pharma.us.novartis.com/product/pi/pdf/tobi.pdf for TOBI full Prescribing Information.
For more information about cystic fibrosis, please visit www.cff.org.